Methotrexate megadose followed by folate rescue. II. Clearance patterns in patients receiving sequential megadose infusions
Salasoo, S.; Irving, M.G.; Freedman, A.
Medical Journal of Australia 1(22): 826-828
1976
ISSN/ISBN: 0025-729X PMID: 1085406 Document Number: 109723
In some patients receiving megadose infusions of methotrexate (MTX), the rate of drug clearance decreases with each subsequent infusion. This can be modified by administration of fluids as outlined in the Recommended Protocol. Monitoring of each treatment is needed to assess requirements of fluids since these cannot be adequately predicted from data of previous infusions.
Document emailed within 1 workday
Related Documents
Panasci, L.; Gravenor, D.; Black, M.; Frenkiel, S.; Margolese, R. 1985: Alternating combination chemotherapy using cisplatin-bleomycin with sequential methotrexate-5-FU plus leucovorin rescue in patients with head and neck cancer Cancer Treatment Reports 69(9): 1015-1017Silverman, E.D.; Myones, B.L.; Miller, J.J. 1984: Lymphocyte subpopulation alterations induced by intravenous megadose pulse methylprednisolone Journal of Rheumatology 11(3): 287-290
Chuenkongkaew, W.; Chirapapaisan, N. 2002: A prospective randomized trial of megadose methylprednisolone and high dose dexamethasone for traumatic optic neuropathy Journal of the Medical Association of Thailand 85(5): 597-603
Kodama, M.; Oyama, A.; Takagi, H. 2008: Control of interstitial pneumonia by drip infusion of megadose vitamin C, dehydroepiandrosterone and cortisol. A short review of our experience In Vivo 22(2): 263-267
Schylla, A.; Scisło, P.; Badura-Brzoza, K.; Pasierb, N. 2012: Description of a patient with schizophrenia and coexisting megadose lorazepam dependence with slightly expressed withdrawl symptoms during drug reduction. A case report Wiadomosci Lekarskie 65(4): 243-246
Nixon, P.F.; Wilson, L. 1983: Identical efficacy of methotrexate regimens with N5-methyltetrahydrofolate rescue or with leucovorin rescue for treatment of L1210 murine leukemia Cancer Treatment Reports 67(1): 59-62
Cadman, E.C.; Glick, J.H.; Cross, J.; Horton, J.; Taylor, S.G. 1984: Sequential methotrexate and 5-FU in CMFP (cyclophosphamide, methotrexate, 5-FU, and prednisone) therapy for breast cancer Cancer Treatment Reports 68(6): 877-879
Lichtiger, B.; Rogge, K. 1991: Spurious serologic test results in patients receiving infusions of intravenous immune gammaglobulin Archives of Pathology and Laboratory Medicine 115(5): 467-469
Dorr, R.T.; Trinca, C.E.; Griffith, K.; Dombrowsky, P.L.; Salmon, S.E. 1979: Limitations of a portable infusion pump in ambulatory patients receiving continuous infusions of anticancer drugs Cancer Treatment Reports 63(2): 211-213
Witty, L.A.; Steiner, F.; Curfman, M.; Webb, D.; Wheat, L.J. 1992: Disseminated histoplasmosis in patients receiving low-dose methotrexate therapy for psoriasis Archives of Dermatology 128(1): 91-93
Rothenberg, S.P.; de Costa, M.; Iqbal, M.P. 1977: Ligand-binding radioassay for the antifolate compounds: application in patients receiving methotrexate Cancer Treatment Reports 61(4): 575-584
Morgan, S.L.; Baggott, J.E. 2010: Folate supplementation during methotrexate therapy for rheumatoid arthritis Clinical and Experimental Rheumatology 28(5 Suppl. 61): S102-S109
Sevelda, P.; Dittrich, C.; Salzer, H.; Pateisky, N.; Spona, J. 1986: Monitoring the cytotoxic potential of a sequential polychemotherapy (adriamycin/cisplatin-vincristine/cyclophosphamide-high dose methotrexate) in patients with advanced ovarian cancer with the tumor marker CA-125 Cancer Detection and Prevention 9(5-6): 521-528
Takeda, M.; Kawauchi, M.; Nakajima, J.; Furuse, A. 1996: Methotrexate in rescue therapy for xenotransplanted lungs in primates Transplantation Proceedings 28(2): 792-793
Levitt, M.; Mosher, M.B.; DeConti, R.C.; Farber, L.R.; Skeel, R.T.; Marsh, J.C.; Mitchell, M.S.; Papac, R.J.; Thomas, E.D.; Bertino, J.R. 1973: Improved therapeutic index of methotrexate with "leucovorin rescue" Cancer Research 33(7): 1729-1734
Isacoff, W.H.; Morrison, P.F.; Aroesty, J.; Willis, K.L.; Block, J.B.; Lincoln, T.L. 1977: Pharmacokinetics of high-dose methotrexate with citrovorum factor rescue Cancer Treatment Reports 61(9): 1665-1674
Dady, P.J.; Taylor, G.A.; Muindi, J.F.; Calvert, A.H.; Smith, I.E.; Smyth, J.F.; Harrap, K.R. 1981: Methotrexate with thymidine, inosine, and allopurinol rescue: a phase i clinical study Cancer Treatment Reports 65(Suppl 1): 37-43
Rodenhuis, S.; McGuire, J.J.; Sawicki, W.L.; Bertino, J.R. 1987: Effects of methotrexate and of the "nonclassical" folate antagonist trimetrexate on human leukemia cells Leukemia 1(2): 116-120
Chello, P.L.; McQueen, C.A.; DeAngelis, L.M.; Bertino, J.R. 1977: Comparative effects of folate antagonists versus enzymatic folate depletion on folate and thymidine enzymes in cultured mammalian cells Cancer Treatment Reports 61(4): 539-548
Sindhi, R.; Webber, S.; Venkataramanan, R.; McGhee, W.; Phillips, S.; Smith, A.; Baird, C.; Iurlano, K.; Mazariegos, G.; Cooperstone, B.; Holt, D.W.; Zeevi, A.; Fung, J.J.; Reyes, J. 2001: Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus Transplantation 72(5): 851-855